CytoTools AG | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
1,823.70
730.30
3,276.80
1,417.30
2,062.10
Total Accounts Receivable
-
23.00
1.00
-
-
Other Current Assets
42.30
31.30
39.70
60.80
15.50
Total Current Assets
1,866.00
784.60
3,317.50
1,478.10
2,077.70
Net Property, Plant & Equipment
4.60
4.70
5.50
67.30
46.00
Total Investments and Advances
8,237.00
7,929.90
7,529.50
8,487.60
9,992.10
Intangible Assets
127.50
116.80
106.80
96.00
85.60
Other Assets
74.00
-
-
-
300.10
Total Assets
10,309.20
8,836.10
10,959.30
10,128.90
12,501.50
ST Debt & Current Portion LT Debt
-
50.00
13.00
-
1,899.90
Other Current Liabilities
2,007.30
191.00
5.50
18.50
-
Total Current Liabilities
2,007.30
241.00
18.50
18.50
1,899.90
Provision for Risks & Charges
201.60
71.50
74.70
50.60
59.30
Other Liabilities
-
-
-
52.20
-
Total Liabilities
2,208.90
312.50
93.30
121.40
1,959.20
Common Equity (Total)
8,100.30
8,523.60
10,866.00
10,007.50
10,542.30
Total Shareholders' Equity
8,100.30
8,523.60
10,866.00
10,007.50
10,542.30
Total Equity
8,100.30
8,523.60
10,866.00
10,007.50
10,542.30
Liabilities & Shareholders' Equity
10,309.20
8,836.10
10,959.30
10,128.90
12,501.50

About CytoTools

View Profile
Address
Klappacher Strasse 126
Darmstadt Hessen 64285
Germany
Employees -
Website http://cytotools.de
Updated 07/08/2019
CytoTools AG is a biotechnology company, which engages in the research and development of therapies to treat cause of diseases. The company provides treatment options in dermatology, cardiology and angiology, urology, and oncology. Its products and pipeline include DermaPro, CardioClean, Cancer T17-n, and Utisept.